Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tetraphase Pharmaceu (TTPH)

Tetraphase Pharmaceu (TTPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,979
  • Shares Outstanding, K 7,263
  • Annual Sales, $ 7,380 K
  • Annual Income, $ -70,090 K
  • 60-Month Beta 2.33
  • Price/Sales 2.25
  • Price/Cash Flow N/A
  • Price/Book 0.58
Trade TTPH with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -18.46
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 08/13/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -1.28
  • Number of Estimates 1
  • High Estimate -1.28
  • Low Estimate -1.28
  • Prior Year -8.40
  • Growth Rate Est. (year over year) +84.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.17 +1.37%
on 07/27/20
2.66 -17.29%
on 07/07/20
-0.40 (-15.38%)
since 06/26/20
3-Month
1.21 +81.82%
on 04/30/20
3.50 -37.14%
on 05/07/20
+0.90 (+69.23%)
since 04/28/20
52-Week
0.56 +292.86%
on 03/18/20
8.60 -74.42%
on 09/12/19
-4.89 (-68.99%)
since 07/26/19

Most Recent Stories

More News
La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc.

-Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases-

LJPC : 6.22 (unch)
TTPH : 2.20 (-3.51%)
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.

La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights

LJPC : 6.22 (unch)
TTPH : 2.20 (-3.51%)
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.

La Jolla Pharmaceutical Company, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, and Tetraphase...

TTPH : 2.20 (-3.51%)
Tetraphase Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to Melinta

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening...

TTPH : 2.20 (-3.51%)
Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVAâ„¢ to treat serious and life-threatening infections, today announced...

TTPH : 2.20 (-3.51%)
Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVAâ„¢ (eravacycline for injection) to treat serious and life-threatening...

TTPH : 2.20 (-3.51%)
Tetraphase Announces Second Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening...

TTPH : 2.20 (-3.51%)
Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening...

TTPH : 2.20 (-3.51%)
Tetraphase Announces Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA â„¢ (eravacycline for injection) to treat serious and life-threatening...

TTPH : 2.20 (-3.51%)
Tetraphase Announces Determination of Superior Offer and Notice to AcelRx

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline Xeravaâ„¢ (eravacycline for injection) to treat serious and life-threatening...

TTPH : 2.20 (-3.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 2.31
1st Resistance Point 2.25
Last Price 2.20
1st Support Level 2.16
2nd Support Level 2.13
3rd Support Level N/A

See More

52-Week High 8.60
Fibonacci 61.8% 5.53
Fibonacci 50% 4.58
Fibonacci 38.2% 3.63
Last Price 2.20
52-Week Low 0.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar